All In MedTech

FDA Clearance Tracker · P160045-S031

Oncomine Dx Target Test

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 21, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 21, 2022

Approved

Time to decision

362 days

Received Sep 24, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P160045-S031
Device name
Oncomine Dx Target Test
Applicant location
Carlsbad, CA
Received
Sep 24, 2021
Decided
Sep 21, 2022
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160045

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval to expand the intended use of the Oncomine Dx Target Test to include a companion diagnostic indication for the detection of the identification of RET fusions in NSCLC patients, RET mutations in medullary thyroid cancer (MTC) patients and RET fusions in thyroid cancer (TC) patients who may benefit from RETEVMO® (selpercatinib).

Source documents

Other decisions for Life Technologies Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.